Drug Profile

JSM 6427

Alternative Names: JSM-6427

Latest Information Update: 04 Mar 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Discontinued Age-related macular degeneration; Proliferative vitreoretinopathy

04 Mar 2011 Development discontinued for Age-related macular degeneration during 2010
10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations, including JSM 6427 for the treatment of age-related macular degeneration
07 Dec 2007 Jerini Ophthalmic enters into a research collaboration agreement with University College London Institute of Ophthalmology for the development of JSM 6427 in age-related macular degeneration

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com